(VIANEWS) – Crescent Capital BDC (CCAP), Costamare (CMRE), Agree Realty Corporation (ADC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Crescent Capital BDC (CCAP)
36.8% sales growth and 4.48% return on equity
Crescent Capital BDC, Inc. is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.
Earnings Per Share
As for profitability, Crescent Capital BDC has a trailing twelve months EPS of $0.87.
PE Ratio
Crescent Capital BDC has a trailing twelve months price to earnings ratio of 18.85. Meaning, the purchaser of the share is investing $18.85 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.48%.
2. Costamare (CMRE)
26.5% sales growth and 24.98% return on equity
Costamare Inc. owns and charters containerships to liner companies worldwide. As of June 14, 2021, it had a fleet of 81 containerships with a total capacity of approximately 581,000 twenty foot equivalent units and 16 dry bulk vessels with a total capacity of approximately 932,000 DWT. The company was founded in 1974 and is based in Monaco.
Earnings Per Share
As for profitability, Costamare has a trailing twelve months EPS of $4.08.
PE Ratio
Costamare has a trailing twelve months price to earnings ratio of 2.24. Meaning, the purchaser of the share is investing $2.24 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.98%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 25% and positive 26.2% for the next.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Oct 18, 2023, the estimated forward annual dividend rate is 0.46 and the estimated forward annual dividend yield is 5.03%.
Moving Average
Costamare’s worth is below its 50-day moving average of $9.69 and below its 200-day moving average of $9.65.
3. Agree Realty Corporation (ADC)
17.8% sales growth and 3.38% return on equity
Earnings Per Share
As for profitability, Agree Realty Corporation has a trailing twelve months EPS of $1.7.
PE Ratio
Agree Realty Corporation has a trailing twelve months price to earnings ratio of 31.86. Meaning, the purchaser of the share is investing $31.86 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.38%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Oct 29, 2023, the estimated forward annual dividend rate is 2.96 and the estimated forward annual dividend yield is 5.47%.
Volume
Today’s last reported volume for Agree Realty Corporation is 1628800 which is 91.27% above its average volume of 851537.
4. Badger Meter (BMI)
13.7% sales growth and 18.66% return on equity
Badger Meter, Inc. manufactures and markets flow measurement, quality, control, and communication solutions in the United States, Asia, Canada, Europe, Mexico, the Middle East, and internationally. It offers mechanical or static water meters, and related radio and software technologies and services to municipal water utilities. The company also provides flow instrumentation products, including meters, valves, and other sensing instruments to measure and control fluids going through a pipe or pipeline, including water, air, steam, oil, and other liquids and gases to original equipment manufacturers as the primary flow measurement device within a product or system, as well as through manufacturers' representatives. Its flow instrumentation products are used in water/wastewater, heating, ventilating and air conditioning, and corporate sustainability markets. In addition, the company offers ORION Migratable for automatic meter reading; ORION (SE) for traditional fixed network applications; and ORION Cellular for infrastructure-free fixed network meter reading solution, as well as BEACON advanced metering analytics, a secure cloud-hosted software suite that establishes alerts for specific conditions and allows consumer engagement tools that permit end water customers to view and manage their water usage activity. It also serves water utilities, industrial, and other industries. The company sells its products directly, as well as through resellers and representatives. Badger Meter, Inc. was founded in 1905 and is headquartered in Milwaukee, Wisconsin.
Earnings Per Share
As for profitability, Badger Meter has a trailing twelve months EPS of $2.89.
PE Ratio
Badger Meter has a trailing twelve months price to earnings ratio of 47.62. Meaning, the purchaser of the share is investing $47.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.66%.
Volume
Today’s last reported volume for Badger Meter is 123103 which is 23.89% below its average volume of 161754.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 23, 2023, the estimated forward annual dividend rate is 0.95 and the estimated forward annual dividend yield is 0.69%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 36.7% and 22.7%, respectively.
5. Incyte Corporation (INCY)
9.2% sales growth and 9.28% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $1.88.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 28.58. Meaning, the purchaser of the share is investing $28.58 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.28%.
Volume
Today’s last reported volume for Incyte Corporation is 389107 which is 76.64% below its average volume of 1666320.
6. Chemed Corp (CHE)
6.8% sales growth and 28.1% return on equity
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates in two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned branches and independent contractors, and franchised locations. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Earnings Per Share
As for profitability, Chemed Corp has a trailing twelve months EPS of $16.13.
PE Ratio
Chemed Corp has a trailing twelve months price to earnings ratio of 34.36. Meaning, the purchaser of the share is investing $34.36 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.1%.
Moving Average
Chemed Corp’s worth is above its 50-day moving average of $510.71 and higher than its 200-day moving average of $525.18.
7. Marriott International (MAR)
6.2% sales growth and 1446.77% return on equity
Marriott International, Inc. operates, franchises, and licenses hotel, residential, timeshare, and other lodging properties worldwide. The company operates through U.S. and Canada, and International segments. It operates its properties under the JW Marriott, The Ritz-Carlton, Ritz-Carlton Reserve, W Hotels, The Luxury Collection, St. Regis, EDITION, Bvlgari, Renaissance, Le Méridien, Marriott, Sheraton, Westin, Four Points, Delta Hotels by Marriott, Autograph Collection, Tribute Portfolio, Marriott Hotels, Marriott Executive Apartments, Marriott Vacation Club, Gaylord Hotels, Design Hotels, Courtyard, Residence Inn, Fairfield, SpringHill Suites, TownePlace Suites, Protea Hotels, Aloft Hotels, AC Hotels by Marriott, Element Hotels, and Moxy Hotels brand names. It operates properties under 30 brand names in 138 countries and territories. Marriott International, Inc. was founded in 1927 and is headquartered in Bethesda, Maryland.
Earnings Per Share
As for profitability, Marriott International has a trailing twelve months EPS of $9.43.
PE Ratio
Marriott International has a trailing twelve months price to earnings ratio of 20.42. Meaning, the purchaser of the share is investing $20.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1446.77%.
Sales Growth
Marriott International’s sales growth is 10.8% for the ongoing quarter and 6.2% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Aug 15, 2023, the estimated forward annual dividend rate is 2.08 and the estimated forward annual dividend yield is 1.09%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.2%, now sitting on 6.13B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 24.3% and 11.7%, respectively.
